Skip to Main Content

Author Details

Eric Gangl
Oncology R&D
1998
30
17
PMIDPaper TitleJournal TitlePublished Year
36727211Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.J Med Chem2023
36912782Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.Mol Cancer Ther2023
34890209Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes.Mol Pharm2022
34126115Generation of High-Quality Pharmacokinetic Data From Parallel Tail Vein Dosing And Bleeding in Non-cannulated Rats.J Pharm Sci2021
33495510Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy.Commun Biol2021
32988967AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.Clin Cancer Res2020
33335676Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833.ACS Med Chem Lett2020
32910656Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.J Med Chem2020
30408457Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization.Anal Biochem2019
30640465Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.J Med Chem2019
29191131Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying bla<sub>KPC-2</sub>.J Chemother2018
28714680Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.J Med Chem2017
28485934Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.J Med Chem2017
28986473Mouse Red Blood Cell-Mediated Rare Xenobiotic Phosphorylation of a Drug Molecule Not Intended to Be a Kinase Substrate.Drug Metab Dispos2017
27149898Selective Time- and NADPH-Dependent Inhibition of Human CYP2E1 by Clomethiazole.Drug Metab Dispos2016
26652586Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma.Bioanalysis2016
25953419Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.J Med Chem2015
23415679Assessment of cisplatin-induced kidney injury using an integrated rodent platform.Toxicol Appl Pharmacol2013
22177783Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.Bioorg Med Chem Lett2012
22812377Antibiotic optimization and chemical structure stabilization of thiomuracin A.J Med Chem2012
22908966In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound.ACS Chem Biol2012
21295471A new structural alert for benzimidazoles: 2,6-dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk.Bioorg Med Chem Lett2011
21999529Antibacterial optimization of 4-aminothiazolyl analogues of the natural product GE2270 A: identification of the cycloalkylcarboxylic acids.J Med Chem2011
21825297In vitro and in vivo activities of novel, semisynthetic thiopeptide inhibitors of bacterial elongation factor Tu.Antimicrob Agents Chemother2011
12458929Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography-mass spectrometry.J Chromatogr A2002
11403278Detection of in vivo formed DNA adducts at the part-per-billion level by capillary liquid chromatography/microelectrospray mass spectrometry.Anal Chem2001
11774901Reduction of signal suppression effects in ESI-MS using a nanosplitting device.Anal Chem2001
10826682Subatmospheric electrospray interface for coupling of microcolumn separations with mass spectrometry.Electrophoresis2000
10525280Determination of in vitro- and in vivo-formed DNA adducts of 2-amino-3-methylimidazo[4,5-f]quinoline by capillary liquid chromatography/microelectrospray mass spectrometry.Chem Res Toxicol1999
9616191Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.Drug Metab Dispos1998
  • 1 - 30 of 30

Recommended Authors

New York University Grossman School of Medicine
Career Start Year 2009
Number of shared co-authors 0
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University
Career Start Year 2008
Number of shared co-authors 0
University of California San Francisco
Career Start Year 2006
Number of shared co-authors 0
Amunix Pharmaceuticals
Career Start Year 2006
Number of shared co-authors 0
The Ohio State University
Career Start Year 2005
Number of shared co-authors 0
Unit for Pharmacokinetics and Drug Metabolism, University of Gothenburg
Career Start Year 2005
Number of shared co-authors 0
Collegeville
Career Start Year 2004
Number of shared co-authors 0
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade
Career Start Year 2004
Number of shared co-authors 0
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2003
Number of shared co-authors 0
University of Pittsburgh School of Pharmacy
Career Start Year 2002
Number of shared co-authors 0
Clinical Development
Career Start Year 1998
Number of shared co-authors 0
Washington State University
Career Start Year 1996
Number of shared co-authors 0
and of Biochemistry and Pharmacy, University of Tuebingen
Career Start Year 1996
Number of shared co-authors 0
Ohio State University
Career Start Year 1994
Number of shared co-authors 2
Ohio State University
Career Start Year 1994
Number of shared co-authors 0
Universite Paris Saclay
Career Start Year 1994
Number of shared co-authors 0
National Institutes of Health
Career Start Year 1994
Number of shared co-authors 0
University of Louisville
Career Start Year 1991
Number of shared co-authors 0
Blavatnik Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 0
Departamento de Toxicologia y Farmacologia Preclinica
Career Start Year 1989
Number of shared co-authors 0
Novartis
Career Start Year 1988
Number of shared co-authors 0
university of california san diego Health, Center for Advanced Laboratory Medicine
Career Start Year 1988
Number of shared co-authors 0
Department of Pharmaceutical Sciences, Utrecht University
Career Start Year 1987
Number of shared co-authors 1
University of Kansas Medical Center
Career Start Year 1985
Number of shared co-authors 2
ReNeuroGen LLC
Career Start Year 1985
Number of shared co-authors 0
UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill
Career Start Year 1984
Number of shared co-authors 0
Department of Pharmaceutics, University of Florida
Career Start Year 1979
Number of shared co-authors 0
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1968
Number of shared co-authors 0
Institut des Biomolecules Max Mousseron (IBMM), UMR-CNRS 7, Universite Montpellier
Career Start Year 1965
Number of shared co-authors 0
1 Vanderbilt University Medical Center
Career Start Year 1958
Number of shared co-authors 0

Collaborators

Oncology R&D
Co-authored papers 5
Oncology R&D
Co-authored papers 4
Oncology R&D
Co-authored papers 4
Oncology R&D
Co-authored papers 4
Oncology R&D
Co-authored papers 4
Oncology R&D
Co-authored papers 4
Oncology R&D
Co-authored papers 3
Preclinical and Translational Sciences, Inc.
Co-authored papers 3
Oncology R&D
Co-authored papers 2
Oncology R&D
Co-authored papers 2
Oncology R&D
Co-authored papers 2
Oncology R&D
Co-authored papers 2
Oncology R&D
Co-authored papers 2
Oncology R&D
Co-authored papers 2
Oncology R&D
Co-authored papers 2
Co-authored papers 2
School of Clinical Sciences at Monash Health, Monash University
Co-authored papers 1
Oncology R&D
Co-authored papers 1
Oncology R&D
Co-authored papers 1
Oncology R&D
Co-authored papers 1
Co-authored papers 1
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Wellcome Sanger Institute
Co-authored papers 1
Co-authored papers 1
H3 Biomedicine Inc.
Co-authored papers 1
Oncology R&D
Co-authored papers 1
Oncology R&D
Co-authored papers 1
The University of Melbourne
Co-authored papers 1
Oncology R&D
Co-authored papers 1
Peter MacCallum Cancer Centre
Co-authored papers 1